TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects are required to meet the following criteria to be eligible for Randomization into this study:~* Male or female Chinese subjects, 18-75 years of age;~* Subjects must have a diagnosis of OA of the index knee based on American College of Rheumatology criteria with X ray confirmation (a Kellgren Lawrence x ray grade of greater than or equal to 2) (Kellgren J. \& Lawrence J, 1957)~* Subjects must have have an NRS and a WOMAC pain sub scale score of 4 at Screening and at Baseline based on four daily diary entries~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~* History of other disease that may involve the index (painful) knee including inflammatory joint diseases or have had recent surgical intervention on the knee.~* Diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving the first dose of study medication. History of or active gastrointestinal disease (eg, inflammatory bowel disease), a chronic or acute renal or hepatic disorder, or a significant coagulation defect.~* Signs and symptoms of clinically significant cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Meloxicam (Type: OTHER): None
- Placebo (Type: PLACEBO_COMPARATOR): 2 Placebo capsules once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants had all of the following to qualify:~* Chorioamnionitis, defined as either 1) clinical diagnosis of choriomanionitis 2) maternal fever greater than or equal to 100 degrees F in the presence of rupture of membranes or 2 of the following: uterine tenderness, maternal WBC \> 15,000 cells/mm, fetal tachycardia \> 160 bpm, malodorous amniotic fluid, or in preterm group only, rupture of membranes and active preterm labor.~* Gestational age ≥ 24 completed weeks, by first trimester ultrasound or date of last menstrual period.~* No greater than 4 hours from onset of fever or diagnosis.~Exclusion Criteria:~Participants had none of the following:~* Asthma, steroid-dependent~* Clinical sepsis, whether viral or bacterial in nature, defined as fever with signs of cardiovascular compromise in mother (blood pressure \< 90/50, heart rate \> 120 bpm, need for oxygen due to maternal saturations below 92%, pneumonia, pyelonephritis, or meningitis)~* Seizure disorder~* Fetal weight or biparietal diameter less than the 10th% for gestational age~* Suspected major genetic or congenital abnormality~* Fetal distress which demands immediate delivery (poor fetal biophysical profile, late decelerations, sinusoidal fetal heart rate pattern)~* Participation in another therapeutic clinical trial

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine (Type: EXPERIMENTAL): Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
- Control (Type: ACTIVE_COMPARATOR): Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Emotional and Cognitive Control in Late-Onset Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 60-85 years, right-handed;~* Diagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria);~* Age of onset of first episode ≥ 50 years with up to three depressive episodes;~* Severity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) ≥ 20.~Exclusion Criteria:~* Psychotic depression by DSM-IV, i.e., presence of delusions with a SCID-R score higher than 2;~* High suicide risk, i.e. intent or plan to attempt suicide in near future;~* Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse;~* History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are exclusion criteria);~* Dementia: Diagnosis of dementia by DSM-IV;~* Mild Cognitive Impairment (MCI);~* Acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or use of drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal;~* Neurological brain disease and/or history of electroconvulsive therapy;~* History of any use of citalopram or escitalopram during the current episode or need for drugs that may interact with these agents, i.e. drug metabolized by the 2D6 P450 isoenzyme system;~* Current involvement in psychotherapy;~* Contraindications to MRI scanning including cardiac pacemaker, metallic objects and metallic implants contraindicating MRI, cardiac stent, claustrophobia;~* Inability to speak English;~* Corrected visual acuity \< 20/70; Color blindness.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): Target dose 20mg for 12 weeks
- Control (Type: OTHER): Non-psychiatric comparison participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:Adult males and females, 18 to 50 years of age; with documented chronic hepatitis C according to the following criteria: elevated serum alanine aminotransferase (ALT) above the upper limit of normal (40 U/l) on two occasions during the preceding six months; anti-HCV positive anti-body status assessed by second generation enzyme linked immunosorbent assay (Roche Diagnostics, Branchburg, New Jersey, USA); positive polymerase chain reaction for HCV RNA (Cobas Amplicor HCV Monitor v2.0; lower limit of quantitation 50 IU/mL); genotype 4; and criteria for chronic hepatitis C in liver biopsy performed within the preceding year with no signs of cirrhosis or bridging fibrosis on pretreatment liver biopsy.~-~Exclusion Criteria:~* Previous IFN-alpha therapy; other liver diseases such as hepatitis A, hepatitis B, schistosomiasis, autoimmune hepatitis, alcoholic liver disease, drug induced hepatitis, or decompensated liver disease; coinfection with schistosomiasis or human immunodeficiency virus; neutro¬penia (,1 500/mm3); thrombocytopenia (,90 000/mm3); creatinine concentration .1.5 times the upper limit of normal; serum a fetoprotein concentration .25 ng/ml; organ transplant; neoplastic disease; severe cardiac or pulmonary disease; unstable thyroid dysfunction; psychiatric disorder; current pregnancy or breast feeding; or therapy with immunomodulatory agents within the last six months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 24 weeks (patients with RVR)
- 2 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 36 weeks (patients with complete EVR)
- 3 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 48 weeks (patients with partial EVR)
- 4 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 48 weeks (control)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PT003 MDI Dose Confirmation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~Key Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other inclusion/exclusion criteria as defined in the protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PT003 (Dose 1) (Type: EXPERIMENTAL): PT003 MDI Dose 1
- PT003 (Dose 2) (Type: EXPERIMENTAL): PT003 MDI Dose 2
- PT003 (Dose 3) (Type: EXPERIMENTAL): PT003 MDI Dose 3
- PT003 (Dose 4) (Type: EXPERIMENTAL): PT003 MDI Dose 4
- PT001 (Type: EXPERIMENTAL): PT001 MDI
- PT005 (Type: EXPERIMENTAL): PT005 MDI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Seeking care at the CASO MDM health care center~* Accept to be followed at Saint-Antoine Hospital in the event of a positive test.~Exclusion Criteria:~* Currently under physician's care for viral hepatitis (HBV/HCV-specific) or HIV~* Already has been tested (must give any of the following as evidence):~  * results from HBV and HCV and HIV tests dating at least 3 months back~ * results from HCV and HIV tests dating at least 3 months back and HBV serology indicating that the participant is immunized against HBV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard testing with ELISA (Type: ACTIVE_COMPARATOR): HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
- Rapid testing (Type: EXPERIMENTAL): HBV, HCV, and HIV infection status determined by a rapid test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 to 45 years of age, inclusive~* Body mass index between 19 kg/m2 and 31 kg/m2, inclusive~* Healthy subjects with no clinically significant abnormalities identified by a detailed medical history,~Exclusion Criteria:~* Systolic blood pressure \>130 mmHg or \<90 mmHg measured after 10 minutes in the supine position at Screening or at admission to the study center~* Heart rate \>90 bpm or \<45 bpm measured after 10 minutes in the supine position~* Electrocardiogram (ECG) finding of QTc interval \>500 msec, or other clinically significant ECG abnormality at the Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- TR-701 FA with Tyramine (Type: EXPERIMENTAL): TR-701 FA 200 oral with Tyramine
- Placebo-controlled with Tyramine (Type: PLACEBO_COMPARATOR): Placebo-controlled with Tyramine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~healthy male and female subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 10773/linagliptin FDC SID (Type: EXPERIMENTAL): medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
- BI 10773/linagliptin SID (Type: EXPERIMENTAL): medium single dose of mono components BI 10773/linagliptin
- BI 10773/linagliptin FDC (Type: EXPERIMENTAL): medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
- BI 10773/linagliptin (Type: EXPERIMENTAL): medium single dose of BI 10773/linagliptin FDC (Formulation A3)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children, 2 to 10 years of age who have up to date routine childhood vaccination, according to U.S. ACIP recommendations~Exclusion Criteria:~1. Unwilling or unable to give written informed assent or consent to participate in the study.~2. Perceived to be unreliable or unavailable for the duration of the study period.~3. Previous confirmed or suspected disease caused by N. meningitidis.~4. Previously immunized with a meningococcal vaccine (licensed or investigational).~5. Receipt of any investigational or non-registered product within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study.~6. Receipt or plan to receive any vaccines within 30 days before and after administration of each dose of the study vaccine.~   (certain exceptions influenza vaccines apply)~7. Significant acute infection within the 7 days prior to enrolment or body temperature of 38°C or greater within 3 days prior to enrolment.~8. Previous serious acute, chronic or progressive disease, epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.~9. History of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components~10. Impairment/alteration of immune function, either congenital or acquired or resulting from (for example):~    * receipt of immunosuppressive therapy,~   * receipt of immunostimulants,~   * receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives.~11. Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- 2 through 5 years (1 Vac) MenACWY-CRM 1 (Type: PLACEBO_COMPARATOR): Subjects 2 through 5 years received one vaccination of MenACWY-CRM
- 2 through 5 years (2 Vac) MenACWY-CRM 2 (Type: ACTIVE_COMPARATOR): Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
- 6 through 10 years (1 Vac) MenACWY-CRM 3 (Type: PLACEBO_COMPARATOR): Subjects 6 through 10 years received one vaccination of MenACWY-CRM
- 6 through 10 years (2 Vac) MenACWY-CRM 4 (Type: ACTIVE_COMPARATOR): Subjects 6 through 10 years received two vaccinations of MenACWY-CRM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke \>4 cigarettes/day for at least a year~* No quit attempt in prior month~* Not planning to quit smoking within next 6 months~* Plan to live in local area for next 8 months~* Meet diagnostic criteria for a current or lifetime Anxiety Disorder or Mood Disorder as determined by the Mini-international Neuropsychiatric Interview~* Read and write in English~* Women not pregnant or nursing and taking steps to avoid pregnancy~* Able to understand and consent to study procedures~Exclusion Criteria:~* Unstable or significant medical condition such as Chronic Obstructive Pulmonary Disease or kidney failure~* Use of non-cigarette nicotine delivery product in the past week or smoking cessation medicine in prior month~* Currently reducing or planning to reduce cigarette consumption in next month~* Uncontrolled serious psychotic illness or substance abuse or inpatient treatment for these in the past 6 months~* Current suicide risk on clinical assessment~* Aged \<18 or \>65~* History of difficulty providing blood samples (fainting, poor venous access)~* Unwilling to remain on one flavor of cigarette (regular or menthol) for the duration of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Reduced Nicotine Content Cigarettes (Type: EXPERIMENTAL): The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
- Usual Nicotine Content Cigarettes (Type: PLACEBO_COMPARATOR): Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, who is 12 years of age or older at Screening visit.~2. Clinical diagnosis of acne vulgaris with facial involvement.~3. An IGA of Moderate (3) or Severe (4) at Baseline visit.~4. A minimum of 20 but not more than 100 inflammatory lesions (papules and pustules) on the face (including the nose) at Baseline visit.~5. A minimum of 30 but not more than 150 non-inflammatory lesions (open comedones and closed comedones) on the face (including the nose) at Baseline visit.~Exclusion Criteria:~1. More than 2 acne nodules on the face at Baseline visit.~2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment.~3. Underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea. This includes clinically significant abnormal findings, uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results, and/or put the subject at significant risk (according to Investigator's judgment) if he/she participates in the clinical trial.~4. The subject has received, applied or taken some specified treatments within the specified timeframe prior to the Baseline visit~5. The subject is unwilling to refrain from use of prohibited medication during the clinical trial.~6. Use of hormonal contraceptives solely for control of acne.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD0271 0.3% /CD1579 2.5% Gel (Type: EXPERIMENTAL): active arm
- CD0271 0.1% / CD1579 2.5% (Type: ACTIVE_COMPARATOR): Comparator arm
- Topical Gel Vehicle (Type: PLACEBO_COMPARATOR): Placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete